← Leaderboards
Jeffrey F. Scherrer
Saint Louis University
$7,609,924
Attributed
$7,609,924
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2014–24$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,609,924 · 5
By mechanism
R01$6,774,582 · 3
R21$835,342 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisUnited States Department Of Veterans AffairsSymptomsMedical RecordsRisk FactorsComorbidityMental DisordersSamplingRecurrenceMental DepressionDisease RemissionUnited StatesPersonsSeveritiesCharacteristicsDesignLinkRecording Of Previous EventsMoodsPrivate SectorRecoveryDoseEnrollmentPathway Interactions
Grant awards (16)
Clinically Meaningful PTSD Improvement: Reducing Risk for Adverse Outcomes in Comorbid Cardiometabolic Disease$404,899
R01 · FY2024 · HL · contact PI
Pathways from Chronic Prescription Opioid Use to New Onset Mood Disorder$547,792
R01 · FY2023 · DA · contact PI
Clinically Meaningful PTSD Improvement: Reducing Risk for Adverse Outcomes in Comorbid Cardiometabolic Disease$414,252
R01 · FY2023 · HL · contact PI
Pathways from Chronic Prescription Opioid Use to New Onset Mood Disorder$608,195
R01 · FY2022 · DA · contact PI
Clinically Meaningful PTSD Improvement: Reducing Risk for Adverse Outcomes in Comorbid Cardiometabolic Disease$451,447
R01 · FY2022 · HL · contact PI
Pathways from Chronic Prescription Opioid Use to New Onset Mood Disorder$665,359
R01 · FY2021 · DA · contact PI
Pathways from Chronic Prescription Opioid Use to New Onset Mood Disorder$683,421
R01 · FY2020 · DA · contact PI
Pathways from Chronic Prescription Opioid Use to New Onset Mood Disorder$650,897
R01 · FY2019 · DA · contact PI
PTSD Treatment: Effects on Health Behavior, Cardiovascular and Metabolic Disease$470,802
R01 · FY2019 · HL · contact PI
PTSD Treatment: Effects on Health Behavior, Cardiovascular and Metabolic Disease$472,715
R01 · FY2018 · HL · contact PI
A Big Data Research Study on the Relationship Between Metformin Use and Dementia$237,338
R21 · FY2018 · AG · contact PI
PTSD Treatment: Effects on Health Behavior, Cardiovascular and Metabolic Disease$691,249
R01 · FY2017 · HL · contact PI
A Big Data Research Study on the Relationship Between Metformin Use and Dementia$206,298
R21 · FY2017 · AG · contact PI
PTSD Treatment: Effects on Health Behavior, Cardiovascular and Metabolic Disease$713,554
R01 · FY2016 · HL · contact PI
Prescription Opioid Analgesics and Risk of Major Depression$189,518
R21 · FY2015 · MH · contact PI
Prescription Opioid Analgesics and Risk of Major Depression$202,188
R21 · FY2014 · MH · contact PI